People · Operator
Named in public records as an officer, director or promoter · active 2023–2023 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Gyre Therapeutics, Inc. | — | Pharmaceuticals | Series A | $5.0M | $34.8M | 2023 |
Charles Wu at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Charles Wu on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Han G. Ying | 1 | 1 |
| Usman G. Nassim | 1 | 1 |
| Weiguo Yu | 1 | 1 |
| Renate Parry | 1 | 1 |
| Ying Luo | 1 | 1 |
| Songjiang Ma | 1 | 1 |
| Thomas Eastling | 1 | 1 |
| Gordon G. Carmichael | 1 | 1 |
| Ruoyu Chen | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.